ArticleRadiation oncology (London, England)2026
Failure modes and effects analysis of LINAC-based stereotactic arrhythmia radioablation categorized by segmental targets.
Article in Radiation oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundStereotactic arrhythmia radioablation (STAR) is an emerging treatment for refractory or recurrent arrhythmias. Compared with conventional stereotactic body radiotherapy (SBRT), STAR involves greater complexity in target delineation, motion management, and organs at risk (OARs) protection, yet it lacks established consensus clinical guidelines, and workflow-specific risk analyses remain limited.
objectiveTo develop a C-arm linear accelerator (LINAC)-based STAR workflow and perform a failure modes and effects analysis (FMEA) with fault tree analysis (FTA), supplemented by an exploratory segment-based anatomical proximity analysis.
methodsA multidisciplinary team constructed a process map for C-arm LINAC-based STAR and identified potential failure modes across the workflow. Risks were scored using occurrence, severity, and detectability to calculate risk priority numbers (RPNs), and FTA was used to analyze causal pathways. In a predefined exploratory imaging subgroup of eight patients with ventricular tachycardia and simulation-acquired coronary computed tomography angiography (CCTA), we divided the left ventricle according to the 17-segment model and measured the minimum distances from each segment to adjacent OARs as an anatomical surrogate of exposure likelihood.
resultsSeventy-nine failure modes were identified, of which 17 were classified as high risk. The highest-risk failure modes were concentrated in target delineation and motion-related steps, including inaccurate multimodal image registration (RPN 432), improper motion evaluation/management (RPN 336), and diagnostic error of arrhythmia substrate definition (RPN 320). In the exploratory imaging subgroup (n = 8), segmental spatial patterns were moderately consistent across patients, with most standard deviations of minimum distance below 2.0 cm, although variability remained for several segment-OAR relationships. Segments 4, 5, and 10 were each located within 2 cm of both the stomach and esophagus, indicating relatively higher anatomical proximity-related risk.
conclusionIn this FMEA of C-arm LINAC-based STAR, the principal high-risk workflow steps were concentrated in substrate definition, image registration, and motion management. The segment-based analysis provides an exploratory anatomical risk-mapping framework for OAR awareness. Further multicenter studies are needed to refine workflow risk prioritization and evaluate the clinical relevance of the segment-based anatomical findings. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.